Corrections to "In Vivo Evidence for a Bridging Role of a Collagen V Subtype at the Epidermis–Dermis Interface"  by unknown
Overexpression of Cathepsin S Induces Chronic Atopic Dermatitis in Mice
Journal of Investigative Dermatology (2012) 132, 2667; doi:10.1038/jid.2012.213; published online 28 June 2012
Correction to: Journal of Investigative Dermatology (2012) 132, 1169–1176; doi:10.1038/jid.2011.404; published online
15 December 2011
In the recent article by Kim et al., some background information was presented incorrectly. Sentences 2 and 3 of the abstract
should read as follows: ‘‘Cysteine protease cathepsin S (CTSS) is involved in inflammatory processes, possibly leading to
atherosclerosis and asthma. Recently, it has been reported that CTSS can arouse a predominant sensation of itch accompanied
by classical ligand–receptor signaling.’’ The authors regret the error.
In Vivo Evidence for a Bridging Role of a Collagen V Subtype at the Epidermis–Dermis Interface
Journal of Investigative Dermatology (2012) 132, 2667; doi:10.1038/jid.2012.214; published online 28 June 2012
Correction to: Journal of Investigative Dermatology (2012) 132, 1841–1849; doi:10.1038/jid.2012.56; published online
22 March 2012
In Figure 5c, the correct y-axis unit is ‘‘fluorescence intensity (535 nm)’’ and not ‘‘OD (578 nm)’’. The revised Figure 5c appears
below.
The protocol for the protein-binding detection described in the Supplementary Data (Materials and Methods, Solid phase assay)
was inexact. The exact procedure is as described here (correction underlined):
Solid phase binding assay
Multiwell plates (96 wells; Dutscher, France) were incubated with 10 mgml1 (100 ml per well) of recombinant procollagen V
homotrimer or fragment (recombinant N-propeptide) dissolved in 20mM Na2CO3 pH 9.2, for 18 h at 4 1C. The wells were then
blocked with 2% milk powder dissolved in 0.05M Tris-HCl, pH 7.2, 0.2 M NaCl (Tris buffer solution). Wells were incubated
with soluble ligand for 2 h at þ4 1C and exposed to a constant amount of diluted polyclonal antibodies against laminin-111.
Wells were then washed with Tris buffer solution and incubated with appropriate fluorescein isothiocyanate-conjugated
secondary antibodies (Jackson Immunoresearch, Beckman Coulter, Roissy, France) for 1 h and fluorescence intensity was
determined at 485–535 nm with a VICTOR X4 Technologies reader (Perkin Elmer SAS, Courtaboeuf, France). Negative control
values, from wells in which the soluble ligands were omitted, were subtracted from the binding data.
The authors regret these errors.
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